NYSE:PHR

Stock Analysis Report

Executive Summary

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.

Share Price & News

How has Phreesia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PHR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.9%

PHR

-3.4%

US Healthcare Services

-2.6%

US Market


1 Year Return

n/a

PHR

11.9%

US Healthcare Services

-13.3%

US Market

Return vs Industry: Insufficient data to determine how PHR performed against the US Healthcare Services industry.

Return vs Market: Insufficient data to determine how PHR performed against the US Market.


Shareholder returns

PHRIndustryMarket
7 Day-12.9%-3.4%-2.6%
30 Day-35.0%-6.7%-15.2%
90 Day-32.5%-3.0%-22.2%
1 Yearn/a12.2%11.9%-11.5%-13.3%
3 Yearn/a62.0%61.1%13.2%5.7%
5 Yearn/a38.2%36.8%31.8%17.2%

Price Volatility Vs. Market

How volatile is Phreesia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Phreesia undervalued compared to its fair value and its price relative to the market?

29.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PHR ($18.3) is trading below our estimate of fair value ($25.84)

Significantly Below Fair Value: PHR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PHR is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: PHR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PHR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PHR is overvalued based on its PB Ratio (6.4x) compared to the US Healthcare Services industry average (3.3x).


Next Steps

Future Growth

How is Phreesia forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

69.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PHR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PHR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PHR's revenue (16.5% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: PHR's revenue (16.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PHR is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Phreesia performed over the past 5 years?

-134.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: PHR is currently unprofitable.

Growing Profit Margin: PHR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PHR's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PHR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (23.3%).


Return on Equity

High ROE: PHR has a negative Return on Equity (-21.18%), as it is currently unprofitable.


Next Steps

Financial Health

How is Phreesia's financial position?


Financial Position Analysis

Short Term Liabilities: PHR's short term assets ($128.7M) exceed its short term liabilities ($32.1M).

Long Term Liabilities: PHR's short term assets ($128.7M) exceed its long term liabilities ($21.3M).


Debt to Equity History and Analysis

Debt Level: PHR's debt to equity ratio (18.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if PHR's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PHR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PHR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Phreesia's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PHR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PHR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PHR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PHR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Chaim Indig (41yo)

5.25s

Tenure

US$510,249

Compensation

Mr. Chaim Indig Co-Founded Phreesia, Inc. in 2005 and serves as its Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under his ...


CEO Compensation Analysis

Compensation vs Market: Chaim's total compensation ($USD510.25K) is below average for companies of similar size in the US market ($USD3.25M).

Compensation vs Earnings: Insufficient data to compare Chaim's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Chaim Indig
Co-Founder5.25yrsUS$510.25k3.06% $20.1m
Evan Roberts
Co-Founder & COO15.25yrsUS$380.12k1.99% $13.1m
Thomas Altier
Chief Financial Officer7.33yrsUS$380.12k0.32% $2.1m
Charles H. Kallenbach
General Counsel & Secretary3.5yrsUS$421.01k0.11% $704.6k
Randy Rasmussen
Chief Accounting Officer0.42yrno datano data
Daniel Nathan
Chief Technology Officer1.17yrsno data0.18% $1.2m
Balaji Gandhi
Vice President of Investor Relationsno datano datano data
Michael Davidoff
Senior Vice President of Marketing & Business Development1.25yrsno data0.31% $2.0m
Garrett Fienberg
Vice President of Sales & Marketing Operationsno datano datano data
Amy VanDuyn
Senior Vice President of Human Resources10yrsno data0.12% $789.4k

4.4yrs

Average Tenure

46yo

Average Age

Experienced Management: PHR's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Chaim Indig
Co-Founder5.25yrsUS$510.25k3.06% $20.1m
Edward Cahill
Independent Director12.5yrsno datano data
Michael Weintraub
Chairman15.25yrsUS$342.50k0.42% $2.8m
Richard Jackson
Member of Medical Advisory Boardno datano datano data
Gillian Munson
Independent Director0.83yrno datano data
Elsa-Grace Giardina
Member of Medical Advisory Boardno datano datano data
Mark Blais
Member of Medical Advisory Boardno datano datano data
Michael Brodman
Member of Medical Advisory Boardno datano datano data
Lee Schwamm
Member of Medical Advisory Boardno datano datano data
Mark Smith
Independent Director1.5yrsUS$186.40kno data

5.3yrs

Average Tenure

57yo

Average Age

Experienced Board: PHR's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PHR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: PHR only recently listed within the past 12 months, with total shares outstanding growing by 591.1% in the past year..


Top Shareholders

Company Information

Phreesia, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Phreesia, Inc.
  • Ticker: PHR
  • Exchange: NYSE
  • Founded: 2005
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$657.415m
  • Shares outstanding: 35.89m
  • Website: https://www.phreesia.com

Number of Employees


Location

  • Phreesia, Inc.
  • 432 Park Avenue South
  • 12th Floor
  • New York
  • New York
  • 10016
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHRNYSE (New York Stock Exchange)YesCommon StockUSUSDJul 2019
19PBST (Boerse-Stuttgart)YesCommon StockDEEURJul 2019
19PDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2019

Biography

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company’s Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, including through Phreesia Mobile, a patients’ mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company’s Phreesia Platform provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients, healthcare provider organizations, and life sciences companies. The company was founded in 2005 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 04:05
End of Day Share Price2020/04/06 00:00
Earnings2019/10/31
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.